Universe Pharmaceuticals INC
UPCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Universe Pharmaceuticals INC focuses on Drug Manufacturers - Specialty & Generic services and products. Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company carries a $2.8M market cap, placing it firmly in the micro-cap category. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Market Cap
$2.8M
Beta
1.46
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-8.07
EPS (Fwd)
—
ROE
-7.2%
ROA
-2.7%
Cash
$33.6M
Total Debt
$9.3M
Free CF
-$10.2M
52W Change
16.2%
Annual Financials
Cash vs Debt
Where UPC stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, UPC finished 30.88% above its 150-day moving average ($3.53) and 21.90% above its 200-day moving average ($3.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UPC overbought or oversold?
At the July 15, 2026 close, UPC's RSI(14) was 54.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Universe Pharmaceuticals INC holds $33.6M in cash against $9.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$10.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -7.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $40.1M (2022) to $17.9M (2025), a 56% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing UPC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.